BRPI0812000A2 - Métodos e composições para administração de oxibutinina - Google Patents

Métodos e composições para administração de oxibutinina

Info

Publication number
BRPI0812000A2
BRPI0812000A2 BRPI0812000-5A2A BRPI0812000A BRPI0812000A2 BR PI0812000 A2 BRPI0812000 A2 BR PI0812000A2 BR PI0812000 A BRPI0812000 A BR PI0812000A BR PI0812000 A2 BRPI0812000 A2 BR PI0812000A2
Authority
BR
Brazil
Prior art keywords
oxybutinine
administration
compositions
methods
oxybutinine administration
Prior art date
Application number
BRPI0812000-5A2A
Other languages
English (en)
Inventor
Michael J Martin
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of BRPI0812000A2 publication Critical patent/BRPI0812000A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0812000-5A2A 2007-05-30 2008-05-30 Métodos e composições para administração de oxibutinina BRPI0812000A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94090707P 2007-05-30 2007-05-30
PCT/US2008/065436 WO2008151092A1 (en) 2007-05-30 2008-05-30 Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number Publication Date
BRPI0812000A2 true BRPI0812000A2 (pt) 2014-11-18

Family

ID=40088519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812000-5A2A BRPI0812000A2 (pt) 2007-05-30 2008-05-30 Métodos e composições para administração de oxibutinina

Country Status (7)

Country Link
US (1) US20080299207A1 (pt)
EP (1) EP2152232A4 (pt)
KR (2) KR20100021451A (pt)
AU (2) AU2008259864C1 (pt)
BR (1) BRPI0812000A2 (pt)
CA (2) CA2859004A1 (pt)
WO (1) WO2008151092A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764405A1 (en) * 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US9119777B2 (en) * 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US20140271796A1 (en) * 2011-10-26 2014-09-18 Hisamitsu Pharmaceutical Co., Inc. Oxybutynin-containing transdermal absorption preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6026809A (en) * 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
EP1191930A2 (en) * 1999-05-20 2002-04-03 Sepracor Inc. Methods for treatment of asthma using s-oxybutynin
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
JP2006504768A (ja) * 2002-10-29 2006-02-09 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 四級アンモニウム化合物
PL1492519T3 (pl) * 2003-03-21 2007-04-30 Dynogen Pharmaceuticals Inc Sposób leczenia chorób dolnych dróg moczowych przez zastosowanie modulatorów podjednostki α2δ kanału wapniowego z modulatorami mięśni gładkich
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
MX2007004976A (es) * 2004-10-25 2007-06-14 Schering Corp Antagonistas de receptor m1 y/o m3 en combinacion con otros compuestos activos para tratar trastornos respiratorios.

Also Published As

Publication number Publication date
EP2152232A1 (en) 2010-02-17
CA2688542A1 (en) 2008-12-11
AU2013257482B2 (en) 2016-07-14
AU2008259864B2 (en) 2013-08-22
EP2152232A4 (en) 2010-06-09
WO2008151092A1 (en) 2008-12-11
US20080299207A1 (en) 2008-12-04
AU2008259864C1 (en) 2014-03-06
KR20100021451A (ko) 2010-02-24
CA2688542C (en) 2016-07-12
CA2859004A1 (en) 2008-12-11
KR20150011379A (ko) 2015-01-30
AU2008259864A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
LTPA2018005I1 (lt) Farmacinė kompozicija
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
RU2493831C3 (ru) Фармацевтические композиции
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
DK2214679T3 (da) Kortikosteroidsammensætninger
BRPI0715712A2 (pt) Composição farmacêutica
DK2068886T3 (da) Lipidholdige præparater
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0813775A2 (pt) Composição
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0814188A2 (pt) Formulações
BRPI0720234A2 (pt) Composição farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0820198A2 (pt) composições farmacêuticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.